Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 285

1.

A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.

Morzaria S, Damrose EJ.

J Voice. 2012 May;26(3):378-80. doi: 10.1016/j.jvoice.2010.07.011. Epub 2010 Oct 16.

PMID:
20951552
2.

Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.

Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND.

Arch Otolaryngol Head Neck Surg. 2004 Apr;130(4):415-20.

PMID:
15096423
3.

Interarytenoid muscle botox injection for treatment of adductor spasmodic dysphonia with vocal tremor.

Kendall KA, Leonard RJ.

J Voice. 2011 Jan;25(1):114-9. doi: 10.1016/j.jvoice.2009.08.003. Epub 2010 Feb 4.

PMID:
20137891
4.

Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.

Braden MN, Johns MM 3rd, Klein AM, Delgaudio JM, Gilman M, Hapner ER.

J Voice. 2010 Mar;24(2):242-9. doi: 10.1016/j.jvoice.2008.08.003. Epub 2009 May 28.

PMID:
19481417
5.

Botulinum toxin treatment of false vocal folds in adductor spasmodic dysphonia: Functional outcomes.

Simpson CB, Lee CT, Hatcher JL, Michalek J.

Laryngoscope. 2016 Jan;126(1):118-21. doi: 10.1002/lary.25515. Epub 2015 Oct 15.

PMID:
26467807
6.

Voice handicap index results for older patients with adductor spasmodic dysphonia.

Wingate JM, Ruddy BH, Lundy DS, Lehman J, Casiano R, Collins SP, Woodson GE, Sapienza C.

J Voice. 2005 Mar;19(1):124-31.

PMID:
15766857
7.

Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.

Young DL, Halstead LA.

J Voice. 2014 Sep;28(5):614-7. doi: 10.1016/j.jvoice.2013.10.024. Epub 2014 Jun 18.

PMID:
24954039
8.

Surgery or botulinum toxin for adductor spasmodic dysphonia: a comparative study.

Mendelsohn AH, Berke GS.

Ann Otol Rhinol Laryngol. 2012 Apr;121(4):231-8.

PMID:
22606926
9.

Correlation of the Voice Handicap Index-10 (VHI-10) and Voice-Related Quality of Life (V-RQOL) in patients with dysphonia.

Romak JJ, Orbelo DM, Maragos NE, Ekbom DC.

J Voice. 2014 Mar;28(2):237-40. doi: 10.1016/j.jvoice.2013.07.015. Epub 2013 Dec 8.

PMID:
24321582
10.

Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.

Orbelo DM, Duffy JR, Hughes Borst BJ, Ekbom D, Maragos NE.

J Voice. 2014 Jan;28(1):123-7. doi: 10.1016/j.jvoice.2013.05.008. Epub 2013 Sep 27.

PMID:
24080335
11.

Combined modality treatment of adductor spasmodic dysphonia.

Silverman EP, Garvan C, Shrivastav R, Sapienza CM.

J Voice. 2012 Jan;26(1):77-86. doi: 10.1016/j.jvoice.2010.08.004. Epub 2011 Feb 3.

PMID:
21292439
12.

Endoscopic laser thyroarytenoid myoneurectomy in patients with adductor spasmodic dysphonia: a pilot study on long-term outcome on voice quality.

Tsuji DH, Takahashi MT, Imamura R, Hachiya A, Sennes LU.

J Voice. 2012 Sep;26(5):666.e7-12. doi: 10.1016/j.jvoice.2011.07.009. Epub 2011 Sep 22.

PMID:
21940146
13.
14.

Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.

Rosow DE, Parikh P, Vivero RJ, Casiano RR, Lundy DS.

Otolaryngol Head Neck Surg. 2013 Jun;148(6):1003-6. doi: 10.1177/0194599813484685. Epub 2013 Mar 27.

PMID:
23535709
15.

Effect of Botulinum Toxin and Surgery among Spasmodic Dysphonia Patients.

van Esch BF, Wegner I, Stegeman I, Grolman W.

Otolaryngol Head Neck Surg. 2017 Feb;156(2):238-254. doi: 10.1177/0194599816675320. Epub 2016 Nov 1. Review.

PMID:
27803079
16.

Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.

Rosow DE, Pechman A, Saint-Victor S, Lo K, Lundy DS, Casiano RR.

J Voice. 2015 May;29(3):352-5. doi: 10.1016/j.jvoice.2014.08.011. Epub 2014 Sep 19.

PMID:
25242042
17.

Abductor paralysis after botox injection for adductor spasmodic dysphonia.

Venkatesan NN, Johns MM, Hapner ER, DelGaudio JM.

Laryngoscope. 2010 Jun;120(6):1177-80. doi: 10.1002/lary.20855.

PMID:
20513036
18.

Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin.

Dejonckere PH, Neumann KJ, Moerman MB, Martens JP, Giordano A, Manfredi C.

Eur Arch Otorhinolaryngol. 2012 Apr;269(4):1195-203. doi: 10.1007/s00405-011-1890-6. Epub 2011 Dec 31.

19.

Efficiency and Cutoff Values of Self-Assessment Instruments on the Impact of a Voice Problem.

Behlau M, Madazio G, Moreti F, Oliveira G, Dos Santos Lde M, Paulinelli BR, Couto Junior Ede B.

J Voice. 2016 Jul;30(4):506.e9-506.e18. doi: 10.1016/j.jvoice.2015.05.022. Epub 2015 Jul 11.

PMID:
26168902
20.

Longitudinal variations of laryngeal overpressure and voice-related quality of life in spasmodic dysphonia.

Yeung JC, Fung K, Davis E, Rai SK, Day AM, Dzioba A, Bornbaum C, Doyle PC.

Laryngoscope. 2015 Mar;125(3):661-6. doi: 10.1002/lary.24953. Epub 2014 Oct 7.

PMID:
25290557

Supplemental Content

Support Center